Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606935 | 0.88 | HDAC1 (0.56) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL27825851 | 0.87 | HDAC1 (0.55) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL8817029 | 0.87 | TDP1 (0.66) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL3954435 | 0.87 | TDP1 (0.66) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL260297 | 0.86 | ALOX5 (0.76) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL22518642 | 0.85 | TDP1 (0.64) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL1629040 | 0.85 | TDP1 (0.64) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL27794216 | 0.85 | ALOX5 (0.74) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL28011381 | 0.84 | ALOX5 (0.54) | ALOX5TDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL3784212 | 0.84 | ALDH1A1 (0.56) | ALOX5ADRB2ADRB1ADRB3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838522-B1 | PHENYLBUTYRATE FOR THE TREATMENT OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-02-21 | — | — | EP | claimed |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-17 | — | — | US | claimed |
| US-20200147016-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | ACER THERAPEUTICS INC. | 2020-05-14 | — | — | US | claimed |
| US-20190151268-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | ACER THERAPEUTICS INC. | 2019-05-23 | — | — | US | claimed |
| EP-2456304-B1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | BAYLOR COLLEGE MEDICINE (US) | 2015-08-19 | — | — | EP | claimed |
| US-20240238230-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | BAYLOR COLLEGE OF MEDICINE | 2024-07-18 | — | — | US | disclosed |
| EP-2838522-B1 | PHENYLBUTYRATE FOR THE TREATMENT OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-17 | — | — | US | disclosed |
| CN-113995743-A | Therapeutic monitoring of phenylacetic acid prodrugs | 伊梅尔迪卡制药公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-111991383-A | Therapeutic monitoring of phenylacetic acid prodrugs | 伊梅尔迪卡制药公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3222275-B1 | METHODS OF THERAPEUTIC MONITORING OF PHENYLACETIC ACID PRODRUGS | IMMEDICA PHARMA AB (SE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200147016-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | ACER THERAPEUTICS INC. | 2020-05-14 | — | — | US | disclosed |
| US-20120022157-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | UCYCLYD PHARMA, INC (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2338050-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | Ucyclyd Pharma, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-2330892-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | Ucyclyd Pharma, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011011781-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010025303-A9 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010025303-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2010-01-14 | — | — | US | disclosed |
| WO-2009134460-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151268-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | OAT, ABAT, BCKDK | ALOX5 2116/4885TDP1 2958/4885HDAC3 2581/4885 |
| US-20240238230-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | OAT, ABAT, BCKDK | ALOX5 2116/4885TDP1 2958/4885HDAC3 2581/4885 |
| US-20120022157-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | PLPBP, GLS, NPPA | ALOX5 1418/4885TDP1 2419/4885HDAC3 825/4885 |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | OAT, SLC1A5, GLS | ALOX5 1232/4885TDP1 2116/4885HDAC3 551/4885 |
| US-20200147016-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | OAT, ABAT, BCKDK | ALOX5 2116/4885TDP1 2958/4885HDAC3 2581/4885 |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | OAT, ABAT, BCKDK | ALOX5 2116/4885TDP1 2958/4885HDAC3 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.